The recent COVID-19 outbreak has highlighted the fact that our knowledge on the pathogenesis and therapy of RNA virus-induced diseases is rather incomplete. Recent studies have shown that the genetic material of RNA viruses undergoes a number of post-transcriptional modifications and these covalent modifications are partly carried out by epigenetic enzymes. Epigenetic modifications affect the stability of RNA molecules, their resistance to nucleases and the translational efficiency of viral RNAs. Epigenetic factors are often well-characterized enzymes and their targeted inhibition, therefore, serve as potential therapeutic targets. Mapping epigenetic modifications in RNA virus genomes and identifying the enzymes that catalyze them will help to identify drugs with therapeutic potential. The objectives of the project are (i) to develop a new method for mapping epigenetic modifications in the viral genome, (ii) to study the effect of selective epigenetic inhibitors on viral replication.